Harvard Infectious Diseases in Adults 2021

[

Harvard Infectious Diseases in Adults 2021
State-of-the-Art Approaches to Prevention, Diagnosis, and Treatment of Infectious Diseases

Highlights of the 2021 Program
Expanded Case-Based and Problem-Solving Education 
The 2021 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions of our national experts in Q and A sessions following the lectures and the workshops.
Treating Highly Resistant Infections, including:

MRSA and VISA (vancomycin-intermediate Staph aureus)
Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
Vancomycin-resistant enterococci (VRE)
Aspergillus and  non-aspergillus mold infections
Candida auris
Nontuberculous mycobacteria (NTM)

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment
Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

Infections in the expanding populations of immunocompromised hosts
Infections in persons with substance use disorders
Infections of travelers and foreign-born persons
Systemic fungal infections
Native and device-related orthopedic infections
Central nervous system (CNS) infections
Ear, nose and throat (ENT) and eye infections
Bronchiectasis and pneumonia
HIV and its infectious and noninfectious complications
PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
Sexually transmitted infections
Hepatitis B and C infections
Tick- and mosquito-borne infections
Vaccines and vaccine-preventable infections
Clostridioides difficile infection

Challenging, Rare, and Emerging Infectious Diseases
Comprehensive updates on:

COVID-19
EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
Re-emergence of vaccine-preventable diseases
Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
Global infectious diseases of clinical importance

Clinical Decision-Making
Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

Selecting the best antimicrobial and duration of treatment
Rapid detection and empiric treatment of the life-threatening infectious diseases
Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral?
Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop

Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

Antimicrobial stewardship to prevent resistance and reduce cost
Infection control, including biothreats
Early inpatient ID consultations to improve outcomes
Strategies for management of infection in persons who inject drugs (PWID)

Optimized for Remote Education
The 2021 program has been enhanced for distance learning. In addition to being live streamed, all sessions will be recorded and made available to participants for online viewing for 30 days after the end of the course.

Reviews
There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

]